Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

3113 - Effect of polypharmacy on treatment preferences and outcome in older breast cancer patients


10 Oct 2016


Poster display


Mehmet Sendur


Annals of Oncology (2016) 27 (6): 43-67. 10.1093/annonc/mdw364


M.A. Sendur1, K. Sılay2, S. Aksoy3, S. Özbek4, N. Ozdemir1, K. Altundag3

Author affiliations

  • 1 Department Of Medical Oncology, Yıldırım Beyazıt University, Faculty of Medicine, 06800 - Ankara/TR
  • 2 Department Of Geriatric Medicine, Yıldırım Beyazıt University, Faculty of Medicine, 06800 - Ankara/TR
  • 3 Department Of Medical Oncology, Hacettepe University Faculty of Medicine, 06100 - Ankara/TR
  • 4 Department Of Internal Medicine, Yıldırım Beyazıt University, Faculty of Medicine, 06800 - Ankara/TR


Abstract 3113


In older cancer patients, polypharmacy is at least as common as it is in individuals of the same age without cancer. However, information related to polypharmacy in older cancer patients is limited. The aim of this study is to evaluate the prevalence of polypharmacy in older breast cancer patients at the time of diagnosis and its association with treatment preferences and disease outcome.


A total of 418 breast cancer patients who were 65 and older at the time of diagnosis between 2001 and 2014 were retrospectively analyzed. Polypharmacy has been defined according to the number of drugs that an individual takes or to the risk of at least one severe drug interaction. Patients were considered as polypharmacy (Arm A, n = 84) and non-polypharmacy group (Arm B, n = 334). Kaplan–Meier survival analysis was carried out for disease free survival (DFS) and overall survival (OS). Two-sided P values of


The median follow-up time for this analysis was 37.5 months. Patient's clinical and pathological characteristics are well-balanced between two arms. In patients with polypharmacy five year DFS rate was 63.5% whereas in patients without polypharmacy DFS rate was 67.9% (P = 0.699). Five-year overall survival rate in Arm A was 68%, while in Arm B was 75.7% (P = 0.249). The association between polypharmacy and disease outcome was also evaluated in “very old” breast cancer patients who are 80 years and older. In patients with polypharmacy three year DFS rate was 56.1% whereas in patients without polypharmacy, DFS rate was 88.2% (P = 0.031). Three-year overall survival rate was 88.2% and 64.5%, respectively (P = 0.105).


The prognostic effect of polypharmacy which is a common geriatric problem on survival has been evaluated in older breast cancer patients. The association between polypharmacy and DFS was found significant in patients 80 years and older. We believe our study contribute the ongoing research by showing the predictive effect of polypharmacy in very old breast cancer patients

Clinical trial identification

Legal entity responsible for the study





All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings